IL1B and colitis: Similarly, oral administration of another AhR agonist, β-naphthoflavone, was shown to decrease the severity of DSS-induced colitis while reducing pro-inflammatory cytokines such as tumor necrosis factor -α (TNF-α), IL-6, and IL-1β [28].